605 related articles for article (PubMed ID: 12749751)
1. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
Simpson D
BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
[TBL] [Abstract][Full Text] [Related]
2. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
[TBL] [Abstract][Full Text] [Related]
3. CAMPATH-1 antibodies in stem-cell transplantation.
Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
[TBL] [Abstract][Full Text] [Related]
4. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Hale G; Waldmann H
Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
[TBL] [Abstract][Full Text] [Related]
5. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
6. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
[TBL] [Abstract][Full Text] [Related]
7. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
Klangsinsirikul P; Carter GI; Byrne JL; Hale G; Russell NH
Blood; 2002 Apr; 99(7):2586-91. PubMed ID: 11895797
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of CAMPATH-1H in BMT patients.
Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
[TBL] [Abstract][Full Text] [Related]
10. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.
Giralt S
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S36-43. PubMed ID: 16720202
[TBL] [Abstract][Full Text] [Related]
11. New developments in the prophylaxis and treatment of graft versus host disease.
Simpson D
Expert Opin Pharmacother; 2001 Jul; 2(7):1109-17. PubMed ID: 11583062
[TBL] [Abstract][Full Text] [Related]
12. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
Norlin AC; Remberger M
Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Chakrabarti S; Hale G; Waldmann H
Transplant Proc; 2004 Jun; 36(5):1225-7. PubMed ID: 15251298
[TBL] [Abstract][Full Text] [Related]
14. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
15. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia.
Kennedy-Nasser AA; Leung KS; Mahajan A; Weiss HL; Arce JA; Gottschalk S; Carrum G; Khan SP; Heslop HE; Brenner MK; Bollard CM; Krance RA
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1277-84. PubMed ID: 17162209
[TBL] [Abstract][Full Text] [Related]
16. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
[TBL] [Abstract][Full Text] [Related]
17. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
[TBL] [Abstract][Full Text] [Related]
18. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
Novitzky N; Thomas V; du Toit C
Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
[TBL] [Abstract][Full Text] [Related]
19. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
[TBL] [Abstract][Full Text] [Related]
20. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
